NGM Bio Provides Business Highlights and Reports Second Quarter 2021 Financial Results Portfolio News / By Karina Tin August 5, 2021 NGM Bio Provides Business Highlights and Reports Second Quarter 2021 Financial Results Read More »
eFFECTOR Therapeutics Initiates Phase 2a Expansion Cohorts Evaluating Zotatifin in Breast Cancer and KRAS-mutant Non-small Cell Lung Cancer Portfolio News / By Karina Tin August 4, 2021 eFFECTOR Therapeutics Initiates Phase 2a Expansion Cohorts Evaluating Zotatifin in Breast Cancer and KRAS-mutant Non-small Cell Lung Cancer Read More »
Tenaya Therapeutics Announces Closing of Upsized Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares Portfolio News / By Karina Tin August 3, 2021 Tenaya Therapeutics Announces Closing of Upsized Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares Read More »
eFFECTOR Therapeutics Doses First Patient with COVID-19 in Phase 1b Clinical Trial Evaluating Zotatifin as a Host-Targeted Antiviral Agent Portfolio News / By Karina Tin July 22, 2021 eFFECTOR Therapeutics Doses First Patient with COVID-19 in Phase 1b Clinical Trial Evaluating Zotatifin as a Host-Targeted Antiviral Agent Read More »
NGM Announces Completion of Enrollment in Phase 2 CATALINA Study of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration Portfolio News / By Karina Tin July 22, 2021 NGM Announces Completion of Enrollment in Phase 2 CATALINA Study of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration Read More »
MorphoSys to Complete Transformational Acquisition of Constellation Pharmaceuticals, Bolstering Its Position in Hematology-Oncology Portfolio News / By Karina Tin July 15, 2021 MorphoSys to Complete Transformational Acquisition of Constellation Pharmaceuticals, Bolstering Its Position in Hematology-Oncology Read More »
Ribon Therapeutics Secures $65 Million Financing Portfolio News / By Karina Tin July 14, 2021 Ribon Therapeutics Secures $65 Million Financing Read More »
Escient Pharmaceuticals Announces Positive Results From Phase 1 Study Of EP547, An MrgprX4-Targeted Oral Therapy For Cholestatic And Uremic Pruritus Portfolio News / By Karina Tin July 14, 2021 Escient Pharmaceuticals Announces Positive Results From Phase 1 Study Of EP547, An MrgprX4-Targeted Oral Therapy For Cholestatic And Uremic Pruritus Read More »
Nurix Therapeutics Reports Second Quarter Fiscal 2021 Financial Results and Provides a Corporate Update Portfolio News / By Karina Tin July 13, 2021 Nurix Therapeutics Reports Second Quarter Fiscal 2021 Financial Results and Provides a Corporate Update Read More »
Tenaya Therapeutics Unveils Preclinical Research Supporting Product Candidate for Rare and Prevalent Heart Disease Indications at ESC Heart Failure 2021 Portfolio News / By Karina Tin July 12, 2021 Tenaya Therapeutics Unveils Preclinical Research Supporting Product Candidate for Rare and Prevalent Heart Disease Indications at ESC Heart Failure 2021 Read More »
